Page last updated: 2024-08-21

pyrazines and tacrolimus

pyrazines has been researched along with tacrolimus in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Alyea, EP; Antin, JH; Armand, P; Cutler, C; Garcia, M; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ; Stevenson, KE1
Cook, WJ; Elkins, S; Gaston, RS; Kumar, V; Prendergast, MB; Reddy, V; Sanders, PW1
Gonzalez, ML; Gonzalez-Pinto, IM; Island, ER; Rossique, M; Ruiz, P; Selvaggi, G; Smith, LJ; Solano, JP; Tekin, A; Tryphonopoulos, P; Tsai, HL; Tzakis, AG1
Nishi, S1
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, C; Ho, VT; Kim, HT; Koreth, J; McDonough, SM; Ritz, J; Soiffer, RJ; Stevenson, KE1
McNeil, C1
Chalermphunchai, N; Lelamali, K; Noppakun, K; Sawangduan, V; Sinpanee, T; Vongchaiudomchoke, T1

Reviews

1 review(s) available for pyrazines and tacrolimus

ArticleYear
[Immunosuppressive agents in kidney transplantation].
    Nihon Jinzo Gakkai shi, 2011, Volume: 53, Issue:1

    Topics: Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclosporine; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Pyrazines; Rituximab; Sirolimus; Sphingosine; T-Lymphocytes; Tacrolimus; TOR Serine-Threonine Kinases

2011

Trials

2 trial(s) available for pyrazines and tacrolimus

ArticleYear
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
    Blood, 2009, Oct-29, Volume: 114, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Methotrexate; Pyrazines; Stem Cell Transplantation; Survival Rate; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous

2009
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-10, Volume: 30, Issue:26

    Topics: Adult; Aged; Antilymphocyte Serum; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Pyrazines; Tacrolimus; Unrelated Donors

2012

Other Studies

4 other study(ies) available for pyrazines and tacrolimus

ArticleYear
Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.
    Clinical transplants, 2009

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin kappa-Chains; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Multiple Myeloma; Mycophenolic Acid; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Tacrolimus

2009
Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
    Clinical transplants, 2009

    Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Biopsy; Boronic Acids; Bortezomib; Child, Preschool; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Intestines; Protease Inhibitors; Pyrazines; Short Bowel Syndrome; Tacrolimus; Treatment Outcome; Viscera

2009
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
    Journal of the National Cancer Institute, 2013, Jul-03, Volume: 105, Issue:13

    Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Cyclohexanes; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunosuppressive Agents; Maraviroc; Methotrexate; Pentostatin; Peripheral Blood Stem Cell Transplantation; Pyrazines; Quality of Life; Tacrolimus; Triazoles; Vorinostat

2013
Modification of immunosuppressive agents in a kidney transplant recipient with COVID-19 and acute kidney injury.
    Journal of infection in developing countries, 2021, 09-30, Volume: 15, Issue:9

    Topics: Acute Kidney Injury; Adult; Amides; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Lopinavir; Male; Mycophenolic Acid; Pyrazines; Ritonavir; Steroids; Tacrolimus; Thailand; Transplant Recipients

2021